Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Tax Provisions (2022 - 2024)

Historic Tax Provisions for Zentalis Pharmaceuticals (ZNTL) over the last 3 years, with Q4 2024 value amounting to -$205000.0.

  • Zentalis Pharmaceuticals' Tax Provisions fell 5185.19% to -$205000.0 in Q4 2024 from the same period last year, while for Sep 2025 it was -$205000.0, marking a year-over-year decrease of 18299.6%. This contributed to the annual value of $177000.0 for FY2024, which is 12945.09% up from last year.
  • Per Zentalis Pharmaceuticals' latest filing, its Tax Provisions stood at -$205000.0 for Q4 2024, which was down 5185.19% from -$27000.0 recorded in Q3 2024.
  • Zentalis Pharmaceuticals' Tax Provisions' 5-year high stood at $266000.0 during Q2 2024, with a 5-year trough of -$605000.0 in Q2 2023.
  • Over the past 3 years, Zentalis Pharmaceuticals' median Tax Provisions value was -$5000.0 (recorded in 2022), while the average stood at -$74416.7.
  • Over the last 5 years, Zentalis Pharmaceuticals' Tax Provisions had its largest YoY gain of 22727.27% in 2023, and its largest YoY loss of 365882.35% in 2023.
  • Over the past 3 years, Zentalis Pharmaceuticals' Tax Provisions (Quarter) stood at -$360000.0 in 2022, then soared by 62.5% to -$135000.0 in 2023, then plummeted by 51.85% to -$205000.0 in 2024.
  • Its last three reported values are -$205000.0 in Q4 2024, -$27000.0 for Q3 2024, and $266000.0 during Q2 2024.